ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1603

P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA)

Abhijeet Danve1, Betty Hsiao2 and Phillip Zhang3, 1Yale University, Rocky Hill, CT, 2Yale Rheumatology, New Haven, 3Yale University, New Haven, CT

Meeting: ACR Convergence 2020

Keywords: Disease Activity, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: RAPID3 scores correlate well with disease-specific indices, including the Clinical Disease Activity Index (CDAI) in RA and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in axSpA, and are being widely used in clinical practice1,2. However, being a patient-reported outcome, RAPID3 can be affected by additional sources of pain, including fibromyalgia, prior joint damage, and psychosocial reasons such as anxiety or depression. Adding a physician global estimate (MD Glob) to RAPID3 (we termed it P4 index: pain, physical function, patient global, and physician (MD) global) may add an objective component and help filter out extraneous factors affecting disease activity measurements. In this observational study, we assessed performance of P4 index by comparing it against RAPID3 and CDAI in RA and RAPID3 and BASDAI in axSpA patients.

Methods: Consecutive patients with RA and axSpA under the care of three clinicians at one academic Rheumatology center completed the Multidimensional Health Assessment Questionnaire (MDHAQ) during their clinic visits with RAPID3 scores subsequently calculated. CDAI and BASDAI scores, respectively, were also recorded at the same visit and the clinician would separately report a physician global estimate (MD Glob) in the Electronic Medical Record. P4 score was calculated by adding MD Glob to the RAPID3 score (score range 0 to 40). Statistical significance between all scores was analyzed using Spearman correlation coefficients. Subgroup analysis was performed including only RA and axSpA patients with concomitant osteoarthritis, fibromyalgia, or anxiety/depression.

Results: We enrolled 40 patients with RA and 17 patients with axSpA; additional enrollment was limited by the coronavirus pandemic. Among RA patients, the mean (SD) CDAI was 8.8 (10.1), mean (SD) RAPID3 was 8.48 (7.9), and mean (SD) P4 was 11.2 (9.7). CDAI and RAPID3 correlated significantly (rho=0.91, p< 0.001). CDAI and P4 also correlated significantly and at somewhat higher levels than RAPID3 (rho=0.95, p< 0.001). Similar results were noted in subgroup analysis for RA patients (Table 1). Among axSpA patients, the mean (SD) BASDAI was 4.6 (2.5), mean (SD) RAPID3 was 12.7 (8.1), and mean P4 was 16.7 (9.9). BASDAI and RAPID3 correlated significantly (rho=0.81, p< 0.001). BASDAI and P4 also correlated significantly at a similar level (rho=0.82, p< 0.001). Subgroup analysis of axSpA patients showed similar results (rho=0.87 vs 0.88, see Table 2).

Conclusion: Our study demonstrates a high degree of correlation between P4 index and RAPID3 as well as validated disease-specific activity indices in both RA and axSpA patients. P4 index has an objective component in the form of MD Glob that may help to adjust for extraneous factors affecting disease activity measurement and management decisions. It would be important to confirm our findings in subsequent larger studies. Overall, using the P4 index may be a quick and practical way to more reliably trend disease activity in RA and axSpA.

1. Pincus T, et al. (2010) Arthritis Care & Research, 62(2):181-189.
2. Danve A, et al. (2015) J Clinical Rheumatology, 34:117-124.

Tables 1 and 2


Disclosure: A. Danve, Novartis, 1, 2, Abbvie, 5, Medscape, 5, Peerview, 8; B. Hsiao, None; P. Zhang, None.

To cite this abstract in AMA style:

Danve A, Hsiao B, Zhang P. P4 Index Correlates with RAPID3 and Disease-Specific Indices in Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/p4-index-correlates-with-rapid3-and-disease-specific-indices-in-rheumatoid-arthritis-ra-and-axial-spondyloarthritis-axspa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/p4-index-correlates-with-rapid3-and-disease-specific-indices-in-rheumatoid-arthritis-ra-and-axial-spondyloarthritis-axspa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology